Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$684.43 USD

684.43
8,362,231

+23.94 (3.62%)

Updated Aug 14, 2025 04:00 PM ET

After-Market: $691.03 +6.60 (0.96%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

by Zacks Equity Research

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.

Zacks Equity Research

The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer

by Zacks Equity Research

AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.

Zacks Equity Research

Alexandria (ARE), Eli Lilly to Expand Gateway Labs to San Diego

by Zacks Equity Research

The expansion of Gateway Labs to San Diego reaffirms the strength and depth of the partnership between Alexandria (ARE) and Eli Lilly.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as IBD Market Gains Traction

by Kinjel Shah

As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).

Zacks Equity Research

Is Invesco Large Cap Growth ETF (PWB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWB

Kinjel Shah headshot

3 Large Drug Stocks That Have Outperformed Industry YTD

by Kinjel Shah

Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.

Zacks Equity Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Zacks Equity Research

The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce

by Zacks Equity Research

Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Eli Lilly, Accenture & The TJX Companies

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Accenture plc (ACN) and The TJX Companies, Inc. (TJX).

Zacks Equity Research

Novo Nordisk (NVO) to Expand Manufacturing Site in France

by Zacks Equity Research

Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.

Kinjel Shah headshot

Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More

by Kinjel Shah

Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.

Zacks Equity Research

Eli Lilly (LLY) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

Zacks Equity Research

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Zacks Equity Research

ABBV vs. LLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ABBV vs. LLY: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWB

Zacks Equity Research

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

Zacks Equity Research

Lilly (LLY) to Build $2.5B Plant to Meet Increased Drug Demand

by Zacks Equity Research

Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.

Zacks Equity Research

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

by Zacks Equity Research

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Sanghamitra Saha headshot

Billionaires Bullish on Big Tech: ETFs in Focus

by Sanghamitra Saha

The latest 13-F filings of billionaires indicate that most are still bullish on big techs.

Andrew Rocco headshot

13F Rundown: Tepper, Buffett, Druckenmiller

by Andrew Rocco

Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.

Zacks Equity Research

Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GSEW

Zacks Equity Research

Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential

by Zacks Equity Research

Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 2026.

Zacks Equity Research

Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QUS

Zacks Equity Research

Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FTCS

Zacks Equity Research

Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie

by Zacks Equity Research

Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.